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Abstract
Background: Tetramethyl-piperidine-substituted, B4119 and B4158 have been shown to exhibit antiplasmodial activity.
Objectives: The in vitro antiplasmodial, cytotoxic and oxidative activities of  clofazimine and its analogues, all TMP (tetrameth-
ylpiperidyl)-substituted phenazines except B669, were evaluated in this study.
Methods: The antiplasmodial activity of  the compounds against RB-1 and pfUP10 laboratory strains of  Plasmodium falci-
parum was investigated by flow cytometry. The cytotoxic activity against HeLa cells and oxidative activity were studied employ-
ing colorimetric and cytochrome C reduction assays respectively.
Results: The riminophenazine agents exhibited antiplasmodial action of  varying degrees: B669, B4100 and B4103 showed 
the best activity while B4121 and B4169 exhibited significant activity at 2µg/ml. Clofazimine had no antiplasmodial activity. 
The compounds B4100, B4103, B4121 and B4169 exhibited significant cytotoxic activity against HeLa cells at concentrations 
of  0.5µg/ml and above while B669 was active at 2µg/ml. Clofazimine and B669 tested at a concentration of  0.5µg/ml caused 
enhancement (p ≤ 0.05) of  neutrophil superoxide production when compared to the FMLP control while all the other TMP-de-
rivatives had no effect (p ≥ 0.05).
Conclusion: Tetramethylpiperidyl-subsituted phenazines may potentially be useful antimalarial/antitumor agents with no 
pro-oxidative properties. In vivo studies on the agents relative to these properties are recommended.   
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Introduction
The World Health Organization reported around 207 
million cases of  malaria in 20121.More than 80% of  the 
world’s malaria casualties occur in Africa, involving most-
ly children under the age of  five and pregnant women2,3. 
Interestingly, recent reports indicate a decline in malaria 
cases mitigated by use of  artemisinin-based combination 
therapy (ACT), notably administration of  Coartem™ 
in malaria hit regions, and introduction of  long-lasting 
insecticidal nets (LLIN)4,5,6,7. However, there are reports 
of  emergence of  ACT resistance in South-East Asia8,9. 
The situation thus calls for augmented efforts directed at 
developing new and novel antimalarial agents and other 
drugs that can potentiate the activity of  existing antima-
larials10.
Clofazimine or Lamprene™ is a riminophenazine com-
pound used with dapsone and rifampicin for the treat-
ment of  leprosy11. Clofazimine is highly lipophilic and 
exhibits dose-limiting gastrointestinal toxicity as well as 
dose-related skin pigmentation12. In an effort to minimize 
side-effects and to improve activity, derivatives of  clofaz-
imine, called TMP (tertramethyl-piperidyl) substituted 
phenazines were designed. They differ from clofazimine 
structurally as they contain the TMP group which have 
been extensively studied for a variety of  biological activi-
ty among which are anti-tumor, antimicrobial, antimyco-
bacterial and antimalarial activities. The antimycobacterial 
activity (not isopropyl group in case of  clofazimine) is 
consequent upon substituting on the imino nitrogen at 
position 2 of  the phenazine nucleus13,14 (Fig. 1).
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Their mechanisms of  action in the various experimen-
tal systems have also been shown15,16,17,18. However, an-
tiplasmodial and/or antitumor activity of  other TMP 
phenazines such as B4100, B4103, 4121 and B4169 are 
yet to be fully explored and herein is the backdrop of  
the present study. Thus, the current study expands on the 
existing knowledge on determining the antimalarial, an-
titumor and oxidative activities of  the substituted TMP-
phenazines to further investigate their antimalarial effica-
cy and antitumor drug property.
Materials and methods
Test agents. The molecular structures of  clofazimine and 
TMP-phenazines are shown in Figure 1. The rimino-
phenazine agents were synthesised by Dr JF O’Sullivan 
(Department of  Chemistry, University College Belfield, 
Dublin, Republic of  Ireland). All the agents were dis-
solved in DMSO to a concentration of  2mg/ml and di-
luted further in culture medium supplemented with 10% 
heat-activated FCS (complete culture medium) directly 
before use. Control systems contained the correspond-
ing DMSO concentrations only. Chloroquine disulphate 
was obtained from Sigma Chemicals Co (St. Louis, MO), 
diluted and filter-sterilised in distilled water to a final con-
centration of  10mM.  
Chemicals and reagents. 
Unless indicated, these were obtained from Sigma Chem-
ical Co. (St. Louis, MO).
Parasite strains and culturing conditions. The chloroquine-sen-
sitive (pfUP10) and low grade-resistant (RB-1) laboratory 
strains of  Plasmodium falciparum were maintained in a 
continuous culture system of  human blood group O+ 
erythrocytes and RPMI-140 medium containing human 
AB+ serum as described elsewhere18. Parasite cultures 




*Note that agent B669 is not a TMP-riminophenazine. 
Figure 1
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In vitro antiplasmodial assay. 
Ring-stage parasite culture suspension (2% parasitemia 
and 0.5% final haematocrit) were exposed to chloroquine 
disulphate (0-250  M final concentration). Parasites in 
culture medium and complete culture medium alone re-
spectively served as positive and negative controls. After 
48h incubation at 37OC in an atmosphere of  5% O2/ 
5% CO2/ 90% N2, parasite growth was evaluated by a 
modified flow cytometric method described elsewhere19. 
Levels of  parasite growth were expressed as percentage 
inhibition of  parasite growth ± SEM.
In vitro chloroquine-sensitizing activities of  rimino-
phenazine agents. The ring-stage parasites cultures of  
RB-1 strain was used in this assay. A combination of  sub-
optimal concentrations of  chloroquine (31 and 61   M) 
with the experimental agents (0.125-2 µg/ml) were plated 
and evaluated as indicated above19. The levels of  parasite-
mia were expressed as percentage inhibition of  parasite 
growth.  
Cytotoxicity assay. 
Cytotoxic assays were performed using round-bottom 
96-well tissue culture plates using a Hela (human cer-
vix epithelioid carcinoma) cell line. Cultured cells were 
harvested from 75% confluent tissue culture flasks with 
0.2% trypsin, washed, and resuspended in MEM sup-
plemented with 10% heat-inactivated FCS. To each well 
were added 20 µl of   tissue culture cells (2x106 cells/ml) 
and the volumes were brought to 200 µl with complete 
culture medium, containing the various solvent controls 
or concentrations (0.0625-2 µg/ml) of  the various test 
agents. The plates were incubated for 72 h at 370C in an 
atmosphere of  5% CO2. At the end of  the incubation 
period, culture supernatants were discarded and adherent 
cells were fixed with 10% phosphate-buffered formalin, 
washed with PBS, and stained with 0.02% crystal violet 
dye. Plates were washed in water and left to dry on paper 
towels. The stain was extracted with 10% SDS at 37OC 
for 18 h. The absorbance was measured at 620 nm on a 
Titertrek Multiskan plate reader. Background values (me-
dium only) were subtracted from each reading. Results are 
expressed as percentage inhibition of  cell growth.
Separation of  neutrophils from human peripheral 
blood (Ficoll method). 
Purified neutrophils were prepared from heparinized ve-
nous blood of  healthy adult human volunteers and were 
separated from mononuclear leukocytes by centrifuga-
tion on Histopague-1077 at 300 g for 25 min at 40C. After 
removal of  the plasma and mononuclear cell layers, the 
neutrophil and erythrocyte fractions were sedimented in 
an abundance of  3% gelatin for 15 minutes at 370C to 
remove the red blood cells. The neutrophil-rich superna-
tant was centrifuged at 160 g for 10 min. The cells were 
washed with PBS at 110 g for 10 min. at room temperature 
and the residual red cells were lysed with 0.83% NH4Cl 
solution on ice for 10 min. The cells were washed with 
PBS at 110 g and the resultant pellet resuspended in in-
dicator-free HBSS before use. Neutrophils of  high purity 
(>90%) and viability (>95%) as determined by the Try-
pan blue dye-exclusion test were diluted to 1-2 x107cells/
ml and held on ice before assaying for superoxide anion 
production.        
Super oxide anion production. 
The generation of  superoxide anion by neutrophils was 
assessed by the superoxide dismutase inhibitable reduc-
tion of  cytochrome c as described by Babior and col-
leagues19. Each assay was performed in triplicates. The 
riminophenazine agents (0.5 µg/ml, final concentration) 
were added to pre-warmed neutrophils (1x106cells/ml) 
in indicator-free HBSS. After a 5 min. incubation, 100 µl 
of  SOD (100 units/ml final concentration) were added 
into appropriate tubes followed by 100 µl cytochrome c 
(0.1 mM final concentration). After a further 5 min. in-
cubation, FMLP (0.1 µM) was added as stimulant to ex-
perimental systems. The reactions were terminated after 5 
min. by addition of  ice-cold PBS. A set of  control tubes 
for FMLP alone, solvent systems and baseline parameters 
were included. The tubes were centrifuged for 10 min. 
at 4OC at 100 g. The optical density of  the supernatants 
was measured at 550nm using a Pye Unicam SP1700 ul-
traviolet spectrophotometer. Results were expressed as 
nanomoles reduced cytochrome c/ 106 neutrophils / 5 
min ± SEM.
Statistical analysis
The data obtained were analysed using Excel and Graph 
Pad Prism 5.00. The results are represented as mean ± 
SD for four experiments conducted in triplicate. Levels 
of  statistical significance were calculated using Student’s t 
test, with p ≤ 0.05 considered significant.
ƞ 
ƞ 
African Health Sciences Vol 17 Issue 1, March, 2017   193
Results
Antimalarial activity by chloroquine and TMP-
phenazines.
The anti-growth effect of  chloroquine disulphate (0-250  
   M, final concentration) and TMP-phenazines (0.125-2 
µg/ml) of  the pfUP10 and RB-1 laboratory strains of  
Plasmodium falciparum was measured by a flow cytomet-













As shown, chloroquine exhibited significant activity (p ≤ 
0.05) from 31 ƞ M and higher with IC50 concentrations 
of  24 ƞ  M and 94 ƞ M for the pfUP10 and RB-1 strains 
respectively. The antimalarial effects of  a combination 
of  chloroquine (31 and 61 ƞ  M) with the experimental 
agents (0.125-2µg/ml) did not increase sensitivity of  the 
malaria parasite to chloroquine, but an additive effect was 
observed in chloroquine (62 ƞ  M) combinationswith 0.25 
µg/ml of  B4103 (Results not shown).  Riminophenazine 
compounds (B669, B4100 and B4103; at concentrations 
of  0.5 µg/ml and higher) showed significant (p<0.05) an-
timalarial activity against the RB-1 strain (Fig. 3), whereas 
B4121 and B4169 were only active at the highest concen-
tration of  2 µg/ml. Clofazimine did not exhibit any an-
tiplasmodial activity at any of  the concentrations tested. 
Similar results were obtained with the pfUP10 strain of  
Plasmodium falciparum (Figure 4). The 50% inhibitory 
concentration (IC50) for the agents used in this study are 
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Inhibition of  tumor cell proliferation by TMP-phenazines.
The cytotoxic effect of  the TMP-phenazines (0.0625-2 
µg/ml) against a Hela cell line were evaluated using a col-
orimetric procedure. The results are shown in Figure 5. 
Experimental agents B4100, B4103 and B4121 exhibited 
antitumor activity at concentrations of  0.25 µg/ml and 
higher while B663, B669 and B4169 showed the similar 
activity at concentrations of  0.5 µg/ml and higher. The 
50% inhibitory concentrations (IC50) are indicated in Ta-
ble 2.
Table 1                      
                                     Riminophenazine 
molecule 
RB-1 PfUP10 
      
B663 (µg/ml) >2 >2 
B669 (µg/ml) 0.4± 0.9 0.2± 1 
B4100 (µg/ml) 0.75± 1 0.37± 3 
B4103 (µg/ml) 0.9± 2.1 0.3± 2.2 
B4169 (µg/ml) 1.4± 0.8 1.3± 07 




Riminophenazine agent IC50 value (µg/ml) 
                                                                           B663   
0.38 ± 0.8 
B669 0.75 ± 0.9 
B4100 0.32 ± 2.1 
B4103 0.3 ± 3 
B4121 0.2 ± 0.7 
B4169 
  
0.4 ± 0.3 
 
Superoxide anion production by neutrophils.
Results in Figure 6 show that only B669 and clofazimine 
tested at a concentration of  0.5 µg/ml caused a signifi- 
cant (p < 0.05) enhancement of  neutrophil superoxide 
anion production when compared to the FMLP control. 
The other riminophenazine agents, all TMP-derivatives 
(B4100, B4103, B4121 and B4169), had no significant ef- 
fect on cellular superoxide anion release (p ≥ 0.05).
Discussion
The results of  the present study show that the TMP- 
phenazines, B4100, B4103, 4121 and B4169 studied also 
exhibit in vitro antiplasmodial, antitumor with no pro-
ox- idative activities. The classical riminophenazine agent 
(B663) does not show activity against malaria parasite
and the inclusion of  the TMP group in the phenazine 
nucleus seems to have modified the chemical nature of  
the classical riminophenazines, hence the antiplasmodial, 
antitumor activity recorded. The present result is consis- 
tent with another study where the TMP-phenazine agents 
B4119 and B4158 possessed activity against multidrug re- 
sistant strains of  Plasmodium falciparum by interfering with 
the parasite haemoglobin degradation (to acquire iron for 
nutritional purposes) in erythrocytes17.
Another study has recently documented that a series of  
riminophenazine analogues, (not TMP-phenazines in this 
case), also exhibited in vitro activity against sensi- tive and 
resistant strains of  Plasmodium falciparum as well as against 
different species of  Leishmania promas- tigotes. Their 
antiprotozoal activity in vitro is observable with IC50 in 
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submicromolar concentrations20. Their re- sult which 
corroborates the need for further explorative studies on 
riminophenazines analogues anti-plasmodium, antitumor 
activities among others augments the basis for the pres-
ent study
Van Niekerk and colleagues have also documented the 
potential of  tetramethylpiperidine-substituted phenazines 
to inhibit the proliferation of  intrinsically multidrug re- 
sistant carcinoma cell lines by a dual mechanism of  ac- 
tion13. The methodology of  the present study on anti- 
tumor activity of  these experimental agents differs from 
the methods employed by others on various aspects of  
the experimental setups (cells, agents concentrations, in- 
cubation period and cell proliferation assay method), and 
is suggestive of  better antitumor potential of  these ana- 
logues studied.
The lack of  pro-oxidative activity may be attributable to 
the following: (i) agents were screened at fixed concen- 
trations and might be active at higher or lower concen- 
trations, (ii) agents may require a longer pre-incubation 
period, (iii) use of  other stimuli of  membrane-associated 
oxidative metabolism such as PMA, LPS, calcium iono- 
phore and opsonized zymosan may be necessary and (v) 
it might be essential to evaluate the superoxide scaveng- 
ing property of  the TMP-derivatives.
Conclusion
The antiplasmodial and anti-tumor efficacy of  these ex- 
perimental agents at pharmaceutically relevant concen- 
trations, suggest that they are promising candidates for 
intensive evaluation in experimental animal models for 
malaria and cancer treatments which study is currently in 
progress.
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